Found 29 articles for: "Melanoma"
Longer Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
May 2026 | Volume 25 | Issue 5 | Original Article | 421 | Copyright © May 2026
Background: Melanoma is the leading cause of skin-cancer-related mortality worldwide. Anti-programmed cell death protein-1 therapies, including pembrolizumab, play a critical rol...
Read MoreChronic Kidney Disease and Postoperative Complications Following Mohs Surgery: A Retrospective Cohort Study
May 2026 | Volume 25 | Issue 5 | Editorials | 486 | Copyright © May 2026
Patients With Lichen Planopilaris Are at Increased Risk of Skin Cancer
May 2026 | Volume 25 | Issue 5 | Features | 479 | Copyright © May 2026
The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma
May 2025 | Volume 24 | Issue 5 | Features | 539 | Copyright © May 2025
Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arse...
Read MoreExploring the Scope of Melanoma Educational Content on Instagram
May 2025 | Volume 24 | Issue 5 | Editorials | e34 | Copyright © May 2025
Citation: Swearingen A, Olagun-Samuel C, Sikora M, et al. Exploring the scope of melanoma educational content on Instagram. J Drugs Dermatol. 2025;24(5):e34. doi:10.36849/JDD.8751...
Read MoreCutaneous Immune-Related Adverse Events Associated With Immunotherapy in Patients With Melanoma
May 2025 | Volume 24 | Issue 5 | Original Article | 490 | Copyright © May 2025
Background: Cutaneous immune-related adverse events (irCAEs) have been commonly reported as a consequence of immune checkpoint inhibitors (ICIs) for the treatment of advanced sta...
Read MoreThe Impact of Geographic Dermatologist Density on Melanoma Mortality
May 2025 | Volume 24 | Issue 5 | Editorials | e36 | Copyright © May 2025
Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
February 2025 | Volume 24 | Issue 2 | Case Reports | 205 | Copyright © February 2025
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patie...
Read MoreMetformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study
December 2024 | Volume 23 | Issue 12 | Original Article | 1089 | Copyright © December 2024
Background: There is literature that suggests metformin may play a protective role against the development of non-melanoma skin cancers. Given the significant burden of disease n...
Read MoreMohs Micrographic Surgery for the Treatment of Lentigo Maligna and Lentigo Maligna Melanoma: An Outcomes Study
December 2024 | Volume 23 | Issue 12 | Original Article | 1094 | Copyright © December 2024
Background: Lentigo maligna (LM), a type of melanoma in situ (MIS), usually develops on sun-damaged skin in the elderly. If left untreated, it may advance to the point of dermal ...
Read MoreAdvances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel
September 2024 | Volume 23 | Issue 9 | Original Article | 774 | Copyright © September 2024
Background: Cutaneous melanoma (CM) is associated with a higher mortality rate than most other skin cancers. The purpose of this expert consensus panel was to review the publishe...
Read MoreCase Series of Acral and Mucosal Melanoma in a Diverse Patient Population
August 2024 | Volume 23 | Issue 8 | Case Reports | 683 | Copyright © August 2024
Melanomas affecting acral and mucosal sites have distinct features and are associated with poorer prognosis. Patients of color may be disproportionately affected. Herein we discuss six ethnically...
Read MoreUnderstanding the Association Between Social Determinants of Health and Receipt of Immunotherapy for Melanoma
May 2024 | Volume 23 | Issue 5 | Original Article | 311 | Copyright © May 2024
Purpose: In this review article, we sought to elucidate how the social determinants of health, including socioeconomic status, education, neighborhood or physical environment, ac...
Read MoreInfluence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes
May 2024 | Volume 23 | Issue 5 | Original Article | 306 | Copyright © May 2024
Background: There are no guidelines on when to more strongly recommend sentinel lymph node biopsy (SLNB) for T1b melanomas.
Objective: To examine whether a...
Read MoreBeyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers
May 2024 | Volume 23 | Issue 5 | Original Article | 301 | Copyright © May 2024
With immunotherapy historically focused on cutaneous melanoma, there has been a new wave of systemic medications available for treating non-melanoma skin cancers including basal cell carcinoma (B...
Read MoreThe Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients
February 2024 | Volume 23 | Issue 2 | Original Article | 78 | Copyright © February 2024
Immune checkpoint inhibitors (ICI) are widely utilized for the treatment of malignant melanoma. Interestingly, gastrointestinal microbiome composition has emerged as a predictive biomarker of imm...
Read MoreCheckpoint Inhibitor-Induced Neurotoxicity in a Case of Metastatic Melanoma
December 2023 | Volume 22 | Issue 12 | Case Reports | e25 | Copyright © December 2023
Checkpoint inhibitors (CPIs) are increasingly being used in the treatment of malignant melanoma. While showing promise in metastatic melanoma treatment, CPIs are associated with immune-related ad...
Read MoreFractional Laser for Prevention of Non-melanoma Skin Cancer
September 2023 | Volume 22 | Issue 9 | Features | 953 | Copyright © September 2023
Citation: McCormick ET, Desai S, Nelson K, et al. Fractional laser for prevention of non-melanoma skin cancer. J Drugs Dermatol. 2023;22(9):953-954. doi:10.36849/JDD.2023.NVRN0923...
Read MoreAssessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ
May 2023 | Volume 22 | Issue 5 | Original Article | 457 | Copyright © May 2023
Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maxi...
Read MoreClinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care
December 2022 | Volume 21 | Issue 12 | Original Article | 1347 | Copyright © December 2022
Objective: A 31-gene expression profile (31-GEP) test that predicts metastatic risk in patients with cutaneous malignant melanoma (CMM) has previously been validated and is available ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
